Search

Displaying results 4661 - 4670 of 10000 in total
  1. Drug

    Lancovutide

    go.drugbank.com/drugs/DB05029
    Investigational

    Lancovutide, a peptide antibiotic, is in clinical development for the treatment of cystic fibrosis.

  2. Drug

    Matuzumab

    go.drugbank.com/drugs/DB05101
    Investigational

    Matuzumab (formerly known as the experimental drug, EMD 72000) is a humanized monoclonal antibody used in cancer treatment. … It has a high affinity for EGFR (epithelial growth factor receptor), frequently associated with the growth of blood vessels in malignancy, facilitating tumor growth and survival.

  3. Drug

    Incadronic acid

    go.drugbank.com/drugs/DB06255
    Experimental

    [A14426,A14431,A14427,A202769] Incadronic acid was first described in the literature in 1991.[A202289] … Along with being investigated to treat hypercalcemia of malignancy,[A202862] it has also been investigated in the treatment of myeloma, leukemia, and other cancers.

  4. Drug

    WL-1002

    go.drugbank.com/drugs/DB05346
    Experimental

    WL-1002 is developed by Winston Laboratories which is a topical cream formulation of 075% zucapaicin (also known as civamide), for the treatment of pain due to osteoarthritis.

  5. Drug

    Neocartilage

    go.drugbank.com/drugs/DB05257
    Investigational

    Neocartilage is the only scaffold-free living cartilage graft on the market.

  6. Drug

    D-Tryptophan

    go.drugbank.com/drugs/DB03225
    Experimental

    Tryptophan is one of the 20 standard amino acids, as well as an essential amino acid in the human diet. It is encoded in the standard genetic code as the codon UGG. … The distinguishing structural characteristic of tryptophan is that it contains an indole functional group. It is an essential amino acid as defined by its growth effects on rats.

  7. Drug

    ALKS 27

    go.drugbank.com/drugs/DB05752
    Experimental

    ALKS 27 is an inhaled formulation of trospium chloride for the treatment of chronic obstructive pulmonary disease (COPD).

  8. Drug

    Nirogacestat

    go.drugbank.com/drugs/DB12005
    ApprovedInvestigational

    3 DeFi trial, where a confirmed objective response rate was observed to be 41% compared to 8% with the placebo. … Desmoid tumors are typically characterized by aberrant activation in Notch signaling.

  9. Drug

    PH-284

    go.drugbank.com/drugs/DB05452
    Experimental

    PH-284 is under investigation by Pherin and Organon for the treatment of anorexia nervosa, and loss of appetite and cachexia in cancer and AIDS patients. … Vomeropherins are self-administered by the patient with a metered nasal spray, or nasal aerosol device so that they can bind to peripheral chemosensory receptors in the nasal passages.

  10. Drug

    Etizolam

    go.drugbank.com/drugs/DB09166
    Investigational

    Initially introduced in 1983 in Japan as treatment for neurological conditions such as anxiety and sleep disorders, etizolam is marketed in Japan, Italy and India. … It is not approved for use by FDA in the US; however it remains unscheduled in several states and is legal for research purposes.

    International brands: E1